COMMITTED TO DISCOVERING BEST-IN-CLASS THERAPIES
TO CONQUER INFLAMMATORY and immunologic DISEASES

RAPT Therapeutics to Announce Initial Data from Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications

November 15, 2020



« back to news page